After completing its initial public offering at the end of June, the Stifel conference marked the first big investor conference for Aratana Therapeutics Inc (NASDAQ:PETX). The company highlighted the growing market for pet medications, favorable economics for drug development when compared with human medications, and its three drugs currently in development. Aratana anticipates that the U.S. Food and Drug Administration could approve those drugs in 2016 if all goes well.